Difference between revisions of "Tivozanib (Fotivda)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "==Diseases for which it is established==" to "==Diseases for which it is established ''(work in progress)''==") |
m |
||
| Line 10: | Line 10: | ||
==History of changes in FDA approval== | ==History of changes in FDA approval== | ||
| − | *3/10/2021: Approved for adult patients with relapsed or refractory advanced [[renal cell carcinoma|renal cell carcinoma (RCC)]] following two or more prior systemic therapies. | + | *3/10/2021: Approved for adult patients with relapsed or refractory advanced [[renal cell carcinoma|renal cell carcinoma (RCC)]] following two or more prior systemic therapies. ''(Based on TIVO-3)'' |
==Also known as== | ==Also known as== | ||
Revision as of 16:09, 4 June 2022
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death.[1][2][3]
Diseases for which it is established (work in progress)
Patient drug information
History of changes in FDA approval
- 3/10/2021: Approved for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. (Based on TIVO-3)
Also known as
- Code name: AV-951
- Brand name: Fotivda